English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective: To examine the efficacy of a combination of anticancer agents and cytokine-induced killer (CIK) cell therapy in inoperable pancreato-biliary cancer patients. Methods: We retrospectively reviewed the medical records of 17 inoperable pancreato-biliary cancer patients who were hospitalized from January 2015 to December 2019 in YCH hospital, Korea, and had received at least 5 treatments with CIK-cell therapy. The patients were all on chemotherapy. The major endpoints of the investigation were the overall survival time. Results: A total of 17 patients were enrolled, 8 (47.1%) males and 9 (52.9%) females (n = 17). The mean age was 61.7 ± 7.8 years. In types of cancer, the patients of pancreatic cancer were 6, and biliary tract were 11. At the survival time analysis, 8 patients (47.1%) were still alive, but death occurred in 9 patients (52.9%). The frequency of CIK-cell therapy was 8.2 ± 4.1. The overall median survival time was 553.0 ± 129.9 days (298.4 days 807.6 days) (by Kaplan-Meier Method) which was 6-9 months longer than conventional treatment alone. Conclusion: In this study CIK-cell therapy prolonged the survival of cancer patients without any major side effects when combined with anticancer drugs. A combination of Anticancer agents with cytokine-induced killer (CIK) cell can be a good proposal for improving the treatment outcomes for pancreatic and biliary cancer. *Correspondence to: Jiyoung,Lee, Department of Family Medicine, YCH Kospital, Seoul 06605, Republic of Korea, E-mail: hello.muzzica@gmail.com

The effect of CIK-cell therapy in combination with anticancer agents in patients with inoperable pancreato-biliary cancer